UPDATE: Wedbush Upgrades Anthera Pharmaceutical to Outperform
A report from Wedbush upgrades its rating from Neutral to Outperform on Anthera Pharmaceuticals (NASDAQ: ANTH).
The report states, “Interim analysis demonstrates A-623 is associated with statistically significant B-cell reduction. Anthera announced yesterday that interim data showed a statistically significant B-cell reduction among systemic lupus erythematosus (SLE) patients administered A-623 in the ongoing PEARL-SC study. Recall that PEARL-SC is a randomized double-blind Phase 2b study evaluating monthly and weekly subcutaneous A-623 for SLE with a primary endpoint of clinical improvement according to the SLE responder index at 24 weeks.”
ANTH closed yesterday at $6.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
